Israel is the world leader in patents for medical devices, relative to population size, and second in the patenting of biopharm products, including pharmaceuticals and treatments.
Israel is eighth in the number of patents granted in the life-sciences industry, which may be the most amazing statistic of all, given the amount of time and money companies must invest in getting a product or technology tested and patented.
This week, the Israeli biotech industry was having its annual confer...
LifeBond, a biosurgery device company has completed a $20m fund raising, which
was led by Giza Venture Capital and Aurum Ventures. Also participating in the
round were existing investors: Pitango Venture Capital and Mr. Robert Taub,
GlenRock Israel and The Zitelman Group. LifeBond CEO, Ishay Attar said
"LifeBond is marching forward rapidly to provide solutions for major un-met needs
in surgery. We welcome the new investors to the company”
The start-up company LifeBond, which...
Following the big success of ILSI-BioMed Week: some data on Israeli Life Science industry.
The Israeli Life Science Industry is young and growing. Of the existing 702 companies, 56% were founded during the last decade. A closer look reveals that a quarter (173 companies) of the Industry was established in the last five years. Figure 1 depicts the trend and growth experienced by the industry in the 2001-2010, period. 306 companies were established prior to 2001, with the oldest one, Teva Pharm...
srael is the world's top investor in R&D as a proportion of GDP in 2011, according to the World Competitiveness Index of 59 countries by Switzerland's IMD Business School. Israel is ranked 17th in competitiveness overall, the same as in 2010.
Israel was also ranked first by IMD in the functioning of central banks.
Hong Kong and the US tied for first place in global competitiveness this year, taking over from Singapore, which fell to third place.
The Federation of Israeli Chambers of C...
In 2010, the Israeli Chief Scientist approved a total of NIS 430 million in various program budgets. The R&D Committee alone considered 338 support applications from 193 companies for life science projects. 265 projects were approved for State assistance.
Statistical reports prepared by the Israeli Chief Scientist office towards the ILSI – Biomed Israel 2011 Week, which will open in Tel Aviv next week (May 23-25, 2011), show that the Chief Scientist helped support life science projects in...
Abbott Diagnostics will be attending Biomed 2011 and is interested in discussions with potential collaborators leading toward the development and commercialization of novel IA/CC biomarkers in all therapeutic areas:
o Evidence of clinical utility
o Well characterized antibody development
o Preferably, a developed ELISA format
o Workable, defendable, global IP position
Looking for manager - pre clinical development
• Design and execute pre-clinical studies (in vitro and in vivo)
• Manage academic collaborators and CROs, including interactions with project managers, scientists, statisticians and contract departments
• Write pre-clinical study protocols, reports and SOP
• Report to VP R&D
• At least 3 years experience as a scientific project manager in a biotech or pharmaceutical company
• Proven experience in leading pre clinical activities includi...
The ILSI-BioMed week is closer every day. It will be opened by a keynote address by Mr. Shlomo Yanai, President and CEO of Teva, Israel.
Shlomo Yanai has been the President and Chief Executive Officer of Teva since March 2007.
Prior to joining Teva, Mr. Yanai was President and Chief Executive Officer of Makhteshim-Agan Industries Ltd. from 2003 until 2006. Previously, Mr. Yanai served in the Israel Defense Forces (the "IDF") for 32 years, where he achieved the rank of Major General, t...
Urology stent developer Allium Medical Ltd. (TASE: ALMD) has announced that it plans to merge with another company. Biomedix Incubator Ltd. (TASE:BMDX) owns 25.8% of Allium, which said that the target company is also controlled by Biomedix. The target company is apparently Israel Biomedical Innovations Ltd. (formerly Endogun), whose operations are synergetic with Allium's.
Biomedix owns 18% of IBI, which has technology for connecting tissue within the body without the need for surgery. IB...
Dr. Dalia Megiddo managed 2 venture capital funds: 7 Health Ventures (2006-2010) and InnoMed Ventures, since 2000.
Dr Megiddo has been involved in the Life Science Venture Capital Industry since 1999 and is well recognized as one of the leaders in the healthcare investment community both in Israel and internationally. She is a frequent speaker at local and international meetings and served as a board member at Given Imaging (NASDAQ-GIVN) and Elron (NASDAQ- ELRN). She is also involved in f...